Drugs similar to semaglutide fall into two buckets: other GLP-1 receptor agonists (liraglutide, dulaglutide, exenatide) and the newer incretin combinations that build on the same biology (tirzepatide, retatrutide, orforglipron). All of them mimic gut hormones to curb appetite and lower blood sugar. They differ from semaglutide mainly in dosing frequency, receptor targets, and how much weight they shift.
What makes a drug "similar" to semaglutide?
Semaglutide is a long-acting GLP-1 receptor agonist. A drug is genuinely comparable if it activates the same GLP-1 receptor to produce the same core effects: slowed gastric emptying, increased satiety, and glucose-dependent insulin release. The closest cousins share its weekly or daily injectable peptide design; the more advanced ones add extra receptor targets to push results higher. If you want the underlying pharmacology first, start with GLP-1 receptor agonist drugs.
How do the main alternatives compare to semaglutide?
The table below benchmarks each comparable drug against semaglutide on the factors patients ask about most.
| Drug | Class | Dosing | Peak trial weight loss | Vs. semaglutide |
|---|---|---|---|---|
| Semaglutide | GLP-1 | Weekly inject / daily pill | ~15% (STEP 1) | Reference |
| Tirzepatide | GIP + GLP-1 | Weekly injection | ~22.5% (SURMOUNT-1) | Stronger weight loss |
| Liraglutide | GLP-1 | Daily injection | ~8% (SCALE) | Older, daily, less effective |
| Dulaglutide | GLP-1 | Weekly injection | ~3-4% | Weaker for weight, strong A1c |
| Exenatide | GLP-1 | Weekly/twice daily | ~3-4% | First-gen, now discontinued |
| Retatrutide | GIP + GLP-1 + glucagon | Weekly injection | ~24% (Phase 2) | More potent, not yet approved |
Tirzepatide: the closest and strongest rival
Tirzepatide is the most important drug similar to semaglutide because it usually outperforms it. It is a dual agonist, hitting both the GLP-1 receptor and the GIP receptor, which appears to amplify appetite suppression and metabolic effect. In head-to-head terms, SURMOUNT-1 reported up to 22.5% mean weight loss at 72 weeks versus roughly 15% for semaglutide 2.4 mg in STEP 1, and the SURPASS-2 trial showed tirzepatide beating semaglutide on A1c reduction in type 2 diabetes.
Tirzepatide is sold as Mounjaro (diabetes) and Zepbound (weight and sleep apnea). For the full breakdown, see tirzepatide vs semaglutide and the primer what is tirzepatide.
Liraglutide and dulaglutide: the older GLP-1 cousins
Liraglutide (Victoza, Saxenda)
Liraglutide is a pure GLP-1 agonist like semaglutide but with a much shorter half-life, so it must be injected daily rather than weekly. In the SCALE trial it produced about 8% weight loss, roughly half of semaglutide's result. It is older, cheaper now that generics exist, and a reasonable option for patients who tolerate it. Details in our Saxenda guide.
Dulaglutide (Trulicity)
Dulaglutide is a once-weekly GLP-1 agonist like semaglutide, and the two are often compared directly for diabetes. In the SUSTAIN-7 trial, semaglutide beat dulaglutide on both A1c and weight loss, but dulaglutide remains popular for its simplicity and lack of titration. See the Trulicity guide for where it still fits.
Exenatide: the original GLP-1, now phased out
Exenatide (Byetta, Bydureon) was the first GLP-1 receptor agonist approved, derived from a compound in Gila monster saliva. It worked but required either twice-daily or weekly injection and produced modest weight loss of around 3-4%. By 2026 both formulations have been discontinued as more effective weekly agents took over. It is included here for context, not as a current option.
Retatrutide and orforglipron: the next generation
Retatrutide
Retatrutide is the most talked-about semaglutide successor. It is a triple agonist, adding glucagon-receptor activity on top of GIP and GLP-1, and Phase 2 data in the New England Journal of Medicine showed up to roughly 24% weight loss at 48 weeks, the highest figure reported for any incretin drug. It is not FDA-approved yet and remains in Phase 3 trials, with analysts projecting a possible 2028 launch. Compare the numbers in retatrutide vs semaglutide.
Orforglipron
Orforglipron (Foundayo) is a small-molecule oral GLP-1 agonist approved for weight management in April 2026. Unlike semaglutide it is not a peptide, so it can be taken as a conventional pill without refrigeration. It gives needle-averse patients a GLP-1 alternative in tablet form.
How do side effects compare across the class?
Because every drug here works through the GLP-1 receptor, they share a remarkably similar side-effect profile. The most common complaints are gastrointestinal: nausea, diarrhea, constipation, and vomiting, almost always worst during dose escalation and fading as the body adapts. The FDA labels for semaglutide, tirzepatide, and liraglutide all carry the same boxed warning about thyroid C-cell tumors seen in rodents, and all caution against use in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
Where the differences show up
The molecules that produce more weight loss tend to produce more gastrointestinal load at peak dose, which is one reason tirzepatide and the investigational triple agonists titrate slowly. Daily agents like liraglutide can cause steadier low-grade nausea, while weekly agents concentrate effects around the injection. Pancreatitis and gallbladder events are rare but reported across the whole class, so the safety conversation is more about the family than about any single alternative.
How should you think about switching or choosing?
The practical question is rarely "which is best in a trial" but "which is best for me." Semaglutide remains a strong, well-studied default. Tirzepatide is the move when more weight loss is the goal and cost or coverage allows. Liraglutide or dulaglutide suit patients who tolerate older agents or whose insurance favors generics. Any switch between these drugs is not a one-to-one dose swap, because potency and units differ; it requires a fresh titration under medical supervision.
Route matters as much as molecule
Semaglutide is unusual in that it comes both as a weekly injection and as daily oral tablets (Rybelsus for diabetes, and the oral 25 mg version for weight loss). When people say they want a drug "similar to semaglutide," they sometimes mean a non-injectable one. On that axis, orforglipron is the standout alternative: a true oral GLP-1 agonist that, unlike peptide tablets, is a small molecule and does not depend on a precise empty-stomach routine for absorption. For injection-tolerant patients chasing maximum results, tirzepatide is the comparator; for pill-preferring patients, the oral options matter more than the last few percentage points of efficacy.
What "comparable" does not mean
Similar mechanism does not mean interchangeable strength. A 1 mg dose of semaglutide is not equivalent to 1 mg of tirzepatide or liraglutide; each molecule has its own potency, half-life, and titration ladder. Comparisons like the table above are useful for orientation, but the right starting dose is always drug-specific and set by a prescriber.
Frequently Asked Questions
Is tirzepatide better than semaglutide?
For weight loss, the trial data favor tirzepatide, with up to about 22.5% mean reduction versus roughly 15% for semaglutide. Tirzepatide also edged semaglutide on blood-sugar control in SURPASS-2. "Better" still depends on tolerability, cost, and coverage for the individual.
Are liraglutide and dulaglutide in the same class as semaglutide?
Yes. All three are GLP-1 receptor agonists. Liraglutide is dosed daily and dulaglutide weekly, and both produce less weight loss than semaglutide, but they share the same mechanism and side-effect profile.
What is the strongest drug similar to semaglutide?
Among approved drugs, tirzepatide is the strongest. The investigational triple agonist retatrutide has posted higher weight-loss figures in early trials but is not yet FDA-approved.
Can I take an alternative if semaglutide causes side effects?
Sometimes. Because the alternatives share semaglutide's GLP-1 mechanism, they often share its gastrointestinal side effects, but tolerability varies between molecules and between people. Any change of drug should be decided with a prescriber, not self-directed.
This article is for general information and is not medical advice. Talk to a licensed clinician before starting, stopping, or switching any GLP-1 medication.
